Divi's Laboratories DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.76×	0.76×	0.75×	0.74×	0.77×
	1.10×	1.14×	1.14×	1.18×	1.17×
	31.0%	28.2%	27.4%	23.3%	26.1%
	0.57×	0.57×	0.58×	0.52×	0.56×
	1.20×	1.20×	1.13×	1.14×	1.13×
	17.7%	16.6%	15.4%	12.1%	14.9%
	16.2%	16.2%	15.4%	12.2%	14.9%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

DIVISLAB₹9,664.00

Divi's Laboratories Ltd.

· Pharma & Health

₹ CrorePeersLAURUSLABS COHANCE GLAND TORNTPHARM ZYDUSLIFE MAXHEALTH DRREDDY CIPLAMcap ₹2.56L Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.77	0.74	0.75	0.76	0.76
Interest Burden (Pretax/EBIT) ×	1.17	1.18	1.14	1.14	1.10
EBIT Margin %	26.07	23.29	27.41	28.20	31.02
Asset Turnover ×	0.56	0.52	0.58	0.57	0.57
Financial Leverage (Assets/Equity) ×	1.13	1.14	1.13	1.20	1.20
ROE (5-step product, year-end total equity) %	14.87	12.09	15.36	16.57	17.74
ROE (owners' profit / average owners' equity) %	14.89	12.15	15.35	16.19	16.19

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.